| Prev Close | 38.08 |
| Open | 38.31 |
| Day Low/High | 37.61 / 38.31 |
| 52 Wk Low/High | 24.30 / 45.43 |
| Volume | 522.31K |
Avnet, Inc. (AVT)
37.62
0.46
1.20
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 99.50B |
| Market Cap | 3.77B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
This Value Portfolio Is Producing Valuable Returns, Thank You
Electro Scientific Industries leads a parade of value stocks that have performed quite nicely in a growth-oriented market.
How My Outperforming Value Portfolio Is Bucking the Trend
Despite the disparity this year between growth and value, my 2017 Double Net Value Portfolio is not struggling.
What's Doing Best in New Portfolio? Take a Guess
Double-Net Dividend stocks, which some would call misfits, doing OK so far.
Cramer: There Should Be More Takeovers Where These Came From
Buying's good for the acquirers, which should give other companies ideas.
Happy Early Returns From This Value-Oriented Dividend Portfolio
Just two months after its creation, the portfolio handily is beating the Russell 2000 Index and Russell Microcap Index.
Who's Next? 4 Cash-Rich Names With 'Net' Positives
'Double-nets' have been fertile ground for acquisitions.
A Back-Door Play on Semiconductors
Avnet insiders have been buying up shares.
Movado and 9 Other Deep-Value Dividend Payers Worth Watching
The list is dominated by retailers, of which there are four; that's unfortunate, given the pressure that sector is facing these days.
Catch These Names in My 'Double-Net' Value Portfolio for 2017
An eclectic mix of 20 companies made my cut of stocks trading at 1x to 2x net current asset value.
Avnet Should Snare Value Investor Attention
The electronic components name that recently bought Premier Farnell is undergoing a noteworthy transition.
Cramer: Where'd All the Growth Go?
Checking the gauges for underperformance, none of them look good.
Finding Value Amid Mindless ETF-ization
This is what matters in making more money for your portfolio.
Jim Cramer Says Hold Allergan, as it May Not Take First Bid From Pfizer
Jim Cramer, The Street's Action Alerts PLUS Portfolio Manager and host of CNBC's 'Mad Money,' said Allergan (AGN) is a stock to hold onto.
Let's Get to the Bottom of This
'Old' tech is coming on strong.
Market Punishes the Currency Crowd
It's discounting who needs to be discounted.
There's a Lot Going on Under the Hood
An immense market rotation is happening.
Play Off Some Crackling Volume Spikes
These stocks have seen such spikes in concert with price compression, which tends to amplify volatility.
Cramer: Europe Is the New Swing Factor
The EU recovery has put heavily exposed U.S. techs and industrials in an enviable position.
Cramer: Europe Is Just Starting to Turn
Right as the U.S. becomes worse for business.
AVT, GOOG, AAPL: 3 Stocks on TV
Dan Fitzpatrick, founder of StockMarketMentor.com, details three stocks Jim Cramer discussed on CNBC's "Mad Money" and how to trade them.
Big Bad Days Add Confusion
Sure is plenty of bad but there is good afoot, too.
This Market Forgives and Forgets
As we have seen time and again, weakness really is a buying opportunity.
Isn't Tech Supposed to Rock Now?
We're right in the tech sweet spot and it sure isn't happening.
The Bullish Paradox
Though we are seeing a mixed picture, it is leading to higher prices.
A Weird Moment for Tech
Are things so bad in the space that we have to buy it?
